MedTrace Logo

Role of Early API in Accurately Differentiating Hepatocellular Carcinoma From Dysplastic Nodules in Cirrhotic Patients

NCT07080372 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 73

Last updated 2025-07-23

No results posted yet for this study

Summary

Liver cirrhosis is a common consequence of chronic liver disease, resulting from sustained hepatic injury due to various etiologies. Cirrhosis predisposes individuals to the development of hepatocellular carcinoma (HCC), the most prevalent primary malignancy of the liver. Among cirrhotic patients, distinguishing between hepatocellular carcinoma and dysplastic nodules is crucial for timely diagnosis, treatment planning, and prognostic assessment.

Conditions

  • Dysplastic Nodule

Interventions

DIAGNOSTIC_TEST

assesment

This study aims to assess the role of early arterial phase in detecting and differentiating hepatocellular carcinoma from dysplastic nodules in chronic liver disease patients.

Sponsors & Collaborators

  • Superior University

    lead OTHER

Eligibility

Min Age
5 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-17
Primary Completion
2025-09-01
Completion
2026-02-28

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07080372 on ClinicalTrials.gov